Codex Shifts Amgen’s AI Focus From Coding Tasks to Patient Work
Sean Bruich argues that Codex’s value at Amgen is not in producing more code, but in reducing the routine implementation work that pulls attention away from science and patients. He describes the tool as useful when it abstracts tedious coding and analysis tasks so biostatisticians, geneticists, software engineers and others can focus on better medicines. The impact, in Bruich’s account, comes less from a single large AI initiative than from many small deployments across everyday workflows.
OpenAI·Jun 4, 2026·4 min read
